Search

Your search keyword '"Uemura, Masahito"' showing total 288 results
Start Over Author "Uemura, Masahito"
288 results on '"Uemura, Masahito"'

6. Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura: A Report From the SERF-TTP Research Group and the RADAR Project

Author

Bennett, Charles L., Kim, Benjamin, Zakarija, Anaadriana, Bandarenko, Nicholas, Pandey, Dilip K., Buffie, Charlie G., McKoy, June M., Tevar, Amul D., Cursio, John F., Yarnold, Paul R., Kwaan, Hau C., De Masi, Davide, Sarode, Ravindra, Raife, Thomas J., Kiss, Joseph E., Raisch, Dennis W., Davidson, Charles, Sadler, J. Evan, Ortel, Thomas L., Zheng, X. Long, Kato, Seiji, Matsumoto, Masanori, Uemura, Masahito, and Fujimura, Yoshihiro

Published
2007
Full Text
View/download PDF

11. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score

Author

Takaya, Hiroaki, Uemura, Masahito, Fujimura, Yoshihiro, Matsumoto, Masanori, Matsuyama, Tomomi, Kato, Seiji, Morioka, Chie, Ishizashi, Hiromichi, Hori, Yuji, Fujimoto, Masao, Tsujimoto, Tatsuhiro, Kawaratani, Hideto, Toyohara, Masahisa, Kurumatani, Norio, and Fukui, Hiroshi

Published
2012
Full Text
View/download PDF

23. Abstracts of Selected Papers Presented at the 76th GeneralMeeting of the Japanese Society of Gastroenterology

Author

Munakata, Akihiro, Nakaji, Shigeyuki, Nagasako, Kou, Imai, Yutaka, Sugino, Yoshinori, Cho, Eisai, Ashihara, Tohru, Saitoh, Norio, Sarashina, Hiromi, Kawaura, Akihiko, Tanida, Noritoshi, Tamura, Shinji, Kawata, Sumio, Shimamoto, Chikao, Hirata, Ichiro, Narisawa, Tomio, Yamazaki, Yoshihiko, Iwama, Takeo, Mishima, Yoshio, Ota, S., Terano, A., Arakawa, Tetsuo, Fukuda, Takashi, Saito, Eiichi, Matsuo, Yutaka, Ohtaki, Toshihiro, Asaka, Masahiro, Taniguchi, Yushi, Kimura, Ken, Goto, Hidemi, Tsukamoto, Yoshihisa, Nakamura, Akira, Chiba, Tsutomu, Suyama, Kyoichiro, Yamazaki, Hideo, Hiwatashi, Nobuo, Yoshikawa, Toshikazu, Kondo, Motoharu, Yamamoto, Hisafumi, Okano, Kenichi, Ohnishi, Hiroo, Muto, Yasutoshi, Kawada, N., Mizoguchi, Y., Hashimoto, Naoaki, Ikeda, Yusei, Uemura, Masahito, Kikuchi, Eiryou, Tazuma, Susumu, Kajiyama, Goro, Manabe, Tadao, Ohshio, Gakuji, Kiyosawa, Kendo, Yamauchi, Masayoshi, Fujisawa, Kiyoshi, Kamimura, Tomoteru, Tsuruya, Takashi, Fukui, Hiroshi, Matsumura, Masahiko, Moriwaki, Hisataka, Muto, Yasutoshi, Koshino, Yosuke, Kato, Tomohiro, Nakamura, Toshiyuki, Futagawa, Shunji, Tanaka, Masatoshi, Tanikawa, Kyuichi, and Sato, Shunichi

Published
1992
Full Text
View/download PDF

24. Control Strategy for Rotary Blood Pumps

Author

Ohuchi, Katsuhiro, Kikugawa, Daiki, Takahashi, Kiyofumi, Uemura, Masahito, Nakamura, Makoto, Murakami, Taiji, Sakamoto, Tohru, and Takatani, Setsuo

Published
2001

27. Salvage living donor liver transplantation after percutaneous transluminal angioplasty for recurrent Budd-Chiari syndrome: a case report

Author

Mitoro Akira, Toyohara Masahisa, Yamao Junichi, Nakanishi Keisuke, Aihara Yosuke, Kaji Kosuke, Morioka Chie, Noguchi Ryuichi, Ikenaka Yasuhide, Yamazaki Masaharu, Ko Saiho, Yoshiji Hitoshi, Shirai Yusaku, Sawai Masayoshi, Yoshida Motoyuki, Fujimoto Masao, Uemura Masahito, Nakajima Yoshiyuki, and Fukui Hiroshi

Subjects
Medicine
Abstract

Abstract Introduction Budd-Chiari syndrome is a very rare pathological entity that ultimately leads to liver failure. Several therapeutic modalities, including percutaneous transluminal angioplasty, have been attempted to save the life of patients with Budd-Chiari syndrome. Few reports have described a salvage living donor liver transplantation performed after percutaneous transluminal angioplasty in a patient with acute Budd-Chiari syndrome. Case presentation A 26-year-old Japanese man developed severe progressive manifestations, such as massive ascites and hematemesis due to rupture of esophageal varices. After making several investigations, we diagnosed the case as Budd-Chiari syndrome. We first performed percutaneous transluminal angioplasty to dilate a short-segment stenosis of his inferior vena cava. The first percutaneous transluminal angioplasty greatly improved the clinical manifestations. However, after a year, re-stenosis was detected, and a second percutaneous transluminal angioplasty failed to open the severe stricture of his inferior vena cava. Since our patient had manifestations of acute liver failure, we decided to perform salvage living donor liver transplantation from his brother. The transplantation was successfully performed and all clinical manifestations were remarkably alleviated. Conclusion In cases of recurrent Budd-Chiari syndrome, the blocked hepatic venous outflow is not always relieved, even with invasive therapies. We have to take into account the possibility of adopting alternative salvage therapies if the first therapeutic modalities fail. When invasive therapy such as percutaneous transluminal angioplasty fails, liver transplantation should be considered as an alternative option.

Published
2011
Full Text
View/download PDF

30. NON-ALCOHOLIC STEATOHEPATITIS IN NARA MEDICAL UNIVERSITY HOSPITAL BETWEEN 2003 AND 2008 ; RETROSPECTIVE STUDY WITH CLINICOPATHOLOGIC ANALYSIS

Author

Kongkarnka, Sarawut, Kasai, Takahiko, Uemura, Masahito, Fukui, Hiroshi, and Nonomura, Akitaka

Subjects
Mallory bodies, hepatocyte ballooning, lipogranuloma, steatohepatitis, perivenular/pericellular fibrosis, metabolic syndrome
Abstract

Clinical and pathological features of 50 Japanese patients with biopsy proven non-alcoholic steatohepatitis (NASH) were reviewed. Incidence of NASH patients increased gradually after 2004, up to 8.06% in the series of liver biopsy specimens. Twenty-six were male and twenty-four were female with a mean age of 54.66 years (range 19-80 years old, male: 47.5, female: 62.4 years old). Forty-four percent of patients were preobese with a body mass index (BMI) between 25 and 30, while 28% of the patients were non-obese, and only 28% of the cases were morbidly obese, confirming that Japanese have a greater tendency to develop fatty liver disease than Western people. Dyslipidemia was found in 30%, diabetes mellitus in 34%, and hypertension in 26% of the patients. Abnormally elevated liver function tests were found in up to 90% of the patients and were characteristically mild with 2- to 3- fold elevation from the normal range in the majority of cases. Histological features of the liver were similar to those reported in Western literature; steatosis was found in every patient and most of them were score 1 (34%) and preferential macrovesicular in type. Lobular necroinflammation was typically mild (combined stage 1 and stage 2,98%). Ballooned hepatocytes were frequently observed with characteristic small poorly formed Mallory bodies. Pericellular fibrosis, one of the key histologic features of NASH, was classified in stage 1 in the majority of the patients (54%), with characteristic acinar zone 3 involvement. As for the disease progression, portal fibrosis and/or bridging fibrosis could develop leading to liver cirrhosis (stage 4 NASH) in 10% of the patients.

Published
2009

32. EFFICACY OF INTERFERON THERAPY FOR CHRONIC HEPATITIS C ： A COOPERATIVE STUDY IN ELEVEN HOSPITALS

Author

Yoshikawa, Masahide, Fukui, Hiroshi, Takaya, Akira, Matsumura, Masahiko, Uemura, Masahito, Fukui, Kennichi, Kuriyama, Shigeki, Kikuchi, Eiryou, Yamao, Junichi, Matsumoto, Masami, Matsumura, Yoshinobu, Tsujii, Hiroyuki, Nakano, Hiroshi, and Tsujii, Tadasu

Subjects
liver histology, HCV genotype, HCV titer, chronic hepatitis C, interferon therapy
Abstract

We investigated the influences of liver histology，serum levels of hepatitis C virus (HCV) and HCV genotypes on responsiveness to interferon (IFN) therapy in 342 patients with chronic hepatitis C. Either 9 million units (MU) of lymphoblastoid alpha IFN or 3 MU of recombinant IFN-alpha was administered daily for 2 weeks and then three times a week for 22 weeks. IFN responses were divided into three groups on the basis of the results of polymerase chain reaction (PCR) assay detecting HCV-RNA in serum. Complete response (CR) was defined as sustained elimination of HCV for at least 6 months after treatment，partial response (PR) as HCV elimination for a limited period，non-response (NR) as continuously positive for HCV-RNA in serum. Quantitation of pre-treament HCV-RNA amount in serum was determined by competitive PCR assay in 47 patients. HCV genotyping was performed in 114 patients by PCR with genotype-specific primers. CR was obtained in 97 patients (28.4%)，PR in 104 (30.4%) and NR in 141 (41.2%). IFN responses，represented by CR/PR/NR，were 15/18/11 in 44 patients with chronic persistent hepatitis (CPH)，72/65/73 in 210 patients with chronic aggressive hepatitis (CAH) 2a，and 10/21/57 in 88 patients with CAH2b. CR rate was lower in patients with CAH2b (11.4%) compared to those with CPH (34.1%) or CAH2a (34.3%). Averages of pre-treatment serum HCV-RNA amount (copies/50μl) were 10³·⁵⁵ in 13 CRs，10⁴·⁵⁶ in 17 PRs，and 10⁵·⁹⁵ in 17 NRs. There was a positive correlation between pre-treatment HCV-RNA levels and IFN unresponsiveness. HCV genotyping in 114 patients revealed that HCV type Ⅰ infection was observed in one，type Ⅱ in 94，type Ⅲ in 11，type Ⅳ in 6 and mixed (types Ⅱ and Ⅳ) in 2 patients，and their IFN responses (CR/PR/NR) were 0/0/1，28/26/40，3/5/3，1/3/2 and 0/1/1，respectively.

Published
1994

33. Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis

Author

Uemura, Masahito, Fujimura, Yoshihiro, Ko, Saiho, Matsumoto, Masanori, Nakajima, Yoshiyuki, and Fukui, Hiroshi

Subjects
Article Subject, hemic and lymphatic diseases
Abstract

The liver plays a central role in hemostasis by synthesizing clotting factors, coagulation inhibitors, and fibrinolytic proteins. Liver cirrhosis (LC), therefore, impacts on both primary and secondary hemostatic mechanisms. ADAMTS13 is a metalloproteinase, produced exclusively in hepatic stellate cells, and specifically cleaves unusually large von Willebrand factor multimers (UL-VWFM). Deficiency of ADAMTS13 results in accumulation of UL-VWFM, which induces platelet clumping or thrombi under high shear stress, followed by sinusoidal microcirculatory disturbances and subsequent progression of liver injuries, eventually leading to multiorgan failure. The marked imbalance between decreased ADAMTS13 activity (ADAMTS13 : AC) and increased production of UL-VWFM indicating a high-risk state of platelet microthrombi formation was closely related to functional liver capacity, hepatic encephalopathy, hepatorenal syndrome, and intractable ascites in advanced LC. Some end-stage LC patients with extremely low ADAMTS13 : AC and its IgG inhibitor may reflect conditions similar to thrombotic thrombocytopenic purpura (TTP) or may reflect “subclinical TTP.” Hence, cirrhotic patients with severe to moderate deficiency of ADAMTS13 : AC may be candidates for FFP infusion as a source of ADAMTS13 or for recombinant ADAMTS13 supplementation. Such treatments may improve the survival of patients with decompensated LC.

Published
2011
Full Text
View/download PDF

34. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score.

Author

Takaya, Hiroaki, Uemura, Masahito, Fujimura, Yoshihiro, Matsumoto, Masanori, Matsuyama, Tomomi, Kato, Seiji, Morioka, Chie, Ishizashi, Hiromichi, Hori, Yuji, Fujimoto, Masao, Tsujimoto, Tatsuhiro, Kawaratani, Hideto, Toyohara, Masahisa, Kurumatani, Norio, Fukui, Hiroshi, Takaya, Hiroaki, Uemura, Masahito, Fujimura, Yoshihiro, Matsumoto, Masanori, Matsuyama, Tomomi, Kato, Seiji, Morioka, Chie, Ishizashi, Hiromichi, Hori, Yuji, Fujimoto, Masao, Tsujimoto, Tatsuhiro, Kawaratani, Hideto, Toyohara, Masahisa, Kurumatani, Norio, and Fukui, Hiroshi

Abstract

Aim: Decreased plasma ADAMTS13 activity (ADAMTS13:AC) results in accumulation of unusually large von Willebrand factor multimers and platelet thrombi formation. Our aim was to evaluate whether ADAMTS13:AC is a prognostic marker in patients with liver cirrhosis. Methods: Plasma ADAMTS13:AC and its related parameters were examined in 108 cirrhotic patients. Results: ADAMTS13:AC decreased as the severity of liver disease increased (means: controls 100%, Child A-cirrhotics 79%, Child B-cirrhotics 63%, and Child C-cirrhotics 31%). ADAMTS13:AC markedly decreased in the cirrhotics with hepatorenal syndrome, refractory ascites and hepatic encephalopathy. The cumulative survival time was the shortest (median: 4.5 months) in the cirrhotics with severe to moderate ADAMTS13:AC deficiency (<3-25%), followed by those with mild ADAMTS13:AC deficiency (25-50%), and was the longest in those with normal activity (>50%). In contrast, based on the Child-Turcotte-Pugh (CTP) score, Child C-cirrhotics had the worst survival, but the survival probabilities did not differ between Child A and B cirrhotics. Based on the Model for End-Stage Liver Disease (MELD) score, the survival was the worst for the cirrhotics in the fourth quartile, but it was not different among cirrhotics in the first three quartiles. Cox proportional-hazards regression analysis showed that ADAMTS13:AC and serum albumin were independent factors affecting the survival. Conclusions: ADAMTS13:AC concomitantly decreases as the functional liver capacity decreases. This activity may be a useful prognostic marker that is equal or superior to the CTP score and the MELD score to predict not only the short-term prognosis but also the long-term survival of the cirrhotic patients., 博士（医学）・甲613号・平成26年3月17日

Published
2014

36. EFFICACY OF INTERFERON THERAPY FOR CHRONIC HEPATITIS C ： A COOPERATIVE STUDY IN ELEVEN HOSPITALS

Author

Yoshikawa, Masahide, Fukui, Hiroshi, Takaya, Akira, Matsumura, Masahiko, Uemura, Masahito, Fukui, Kennichi, Kuriyama, Shigeki, Kikuchi, Eiryou, Yamao, Junichi, Matsumoto, Masami, Matsumura, Yoshinobu, Tsujii, Hiroyuki, Nakano, Hiroshi, Tsujii, Tadasu, Yoshikawa, Masahide, Fukui, Hiroshi, Takaya, Akira, Matsumura, Masahiko, Uemura, Masahito, Fukui, Kennichi, Kuriyama, Shigeki, Kikuchi, Eiryou, Yamao, Junichi, Matsumoto, Masami, Matsumura, Yoshinobu, Tsujii, Hiroyuki, Nakano, Hiroshi, and Tsujii, Tadasu

Abstract

We investigated the influences of liver histology，serum levels of hepatitis C virus (HCV) and HCV genotypes on responsiveness to interferon (IFN) therapy in 342 patients with chronic hepatitis C. Either 9 million units (MU) of lymphoblastoid alpha IFN or 3 MU of recombinant IFN-alpha was administered daily for 2 weeks and then three times a week for 22 weeks. IFN responses were divided into three groups on the basis of the results of polymerase chain reaction (PCR) assay detecting HCV-RNA in serum. Complete response (CR) was defined as sustained elimination of HCV for at least 6 months after treatment，partial response (PR) as HCV elimination for a limited period，non-response (NR) as continuously positive for HCV-RNA in serum. Quantitation of pre-treament HCV-RNA amount in serum was determined by competitive PCR assay in 47 patients. HCV genotyping was performed in 114 patients by PCR with genotype-specific primers. CR was obtained in 97 patients (28.4%)，PR in 104 (30.4%) and NR in 141 (41.2%). IFN responses，represented by CR/PR/NR，were 15/18/11 in 44 patients with chronic persistent hepatitis (CPH)，72/65/73 in 210 patients with chronic aggressive hepatitis (CAH) 2a，and 10/21/57 in 88 patients with CAH2b. CR rate was lower in patients with CAH2b (11.4%) compared to those with CPH (34.1%) or CAH2a (34.3%). Averages of pre-treatment serum HCV-RNA amount (copies/50μl) were 10³·⁵⁵ in 13 CRs，10⁴·⁵⁶ in 17 PRs，and 10⁵·⁹⁵ in 17 NRs. There was a positive correlation between pre-treatment HCV-RNA levels and IFN unresponsiveness. HCV genotyping in 114 patients revealed that HCV type Ⅰ infection was observed in one，type Ⅱ in 94，type Ⅲ in 11，type Ⅳ in 6 and mixed (types Ⅱ and Ⅳ) in 2 patients，and their IFN responses (CR/PR/NR) were 0/0/1，28/26/40，3/5/3，1/3/2 and 0/1/1，respectively.

Published
2011

37. NON-ALCOHOLIC STEATOHEPATITIS IN NARA MEDICAL UNIVERSITY HOSPITAL BETWEEN 2003 AND 2008 ; RETROSPECTIVE STUDY WITH CLINICOPATHOLOGIC ANALYSIS

Author

Kongkarnka, Sarawut, Kasai, Takahiko, Uemura, Masahito, Fukui, Hiroshi, Nonomura, Akitaka, Kongkarnka, Sarawut, Kasai, Takahiko, Uemura, Masahito, Fukui, Hiroshi, and Nonomura, Akitaka

Abstract

Clinical and pathological features of 50 Japanese patients with biopsy proven non-alcoholic steatohepatitis (NASH) were reviewed. Incidence of NASH patients increased gradually after 2004, up to 8.06% in the series of liver biopsy specimens. Twenty-six were male and twenty-four were female with a mean age of 54.66 years (range 19-80 years old, male: 47.5, female: 62.4 years old). Forty-four percent of patients were preobese with a body mass index (BMI) between 25 and 30, while 28% of the patients were non-obese, and only 28% of the cases were morbidly obese, confirming that Japanese have a greater tendency to develop fatty liver disease than Western people. Dyslipidemia was found in 30%, diabetes mellitus in 34%, and hypertension in 26% of the patients. Abnormally elevated liver function tests were found in up to 90% of the patients and were characteristically mild with 2- to 3- fold elevation from the normal range in the majority of cases. Histological features of the liver were similar to those reported in Western literature; steatosis was found in every patient and most of them were score 1 (34%) and preferential macrovesicular in type. Lobular necroinflammation was typically mild (combined stage 1 and stage 2,98%). Ballooned hepatocytes were frequently observed with characteristic small poorly formed Mallory bodies. Pericellular fibrosis, one of the key histologic features of NASH, was classified in stage 1 in the majority of the patients (54%), with characteristic acinar zone 3 involvement. As for the disease progression, portal fibrosis and/or bridging fibrosis could develop leading to liver cirrhosis (stage 4 NASH) in 10% of the patients.

Published
2010

38. Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance

Author

YOSHIJI, HITOSHI, primary, NOGUCHI, RYUICHI, additional, NAMISAKI, TADASHI, additional, MORIYA, KEI, additional, KITADE, MITSUTERU, additional, AIHARA, YOSUKE, additional, DOUHARA, AKITOSHI, additional, YAMAO, JUNICHI, additional, FUJIMOTO, MASAO, additional, TOYOHARA, MASAHISA, additional, MITORO, AKIRA, additional, SAWAI, MASAYOSHI, additional, YOSHIDA, MOTOYUKI, additional, MORIOKA, CHIE, additional, UEJIMA, MASAKAZU, additional, UEMURA, MASAHITO, additional, and FUKUI, HIROSHI, additional

Published
2013
Full Text
View/download PDF

39. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study

Author

Narahara, Yoshiyuki, primary, Kanazawa, Hidenori, additional, Sakamoto, Choitsu, additional, Maruyama, Hitoshi, additional, Yokosuka, Osamu, additional, Mochida, Satoshi, additional, Uemura, Masahito, additional, Fukui, Hiroshi, additional, Sumino, Yasukiyo, additional, Matsuzaki, Yasushi, additional, Masaki, Naohiko, additional, Kokubu, Shigehiro, additional, and Okita, Kiwamu, additional

Published
2011
Full Text
View/download PDF

40. Salvage living donor liver transplantation after percutaneous transluminal angioplasty for recurrent Budd-Chiari syndrome: a case report

Author

Shirai, Yusaku, primary, Yoshiji, Hitoshi, additional, Ko, Saiho, additional, Yamazaki, Masaharu, additional, Ikenaka, Yasuhide, additional, Noguchi, Ryuichi, additional, Morioka, Chie, additional, Kaji, Kosuke, additional, Aihara, Yosuke, additional, Nakanishi, Keisuke, additional, Yamao, Junichi, additional, Toyohara, Masahisa, additional, Mitoro, Akira, additional, Sawai, Masayoshi, additional, Yoshida, Motoyuki, additional, Fujimoto, Masao, additional, Uemura, Masahito, additional, Nakajima, Yoshiyuki, additional, and Fukui, Hiroshi, additional

Published
2011
Full Text
View/download PDF

41. Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents

Author

YOSHIJI, HITOSHI, primary, NOGUCHI, RYUICHI, additional, IKENAKA, YASUHIDE, additional, KAJI, KOSUKE, additional, SHIRAI, YUSAKU, additional, AIHARA, YOSUKE, additional, YAMAO, JUNICHI, additional, TOYOHARA, MASAHISA, additional, MITORO, AKIRA, additional, SAWAI, MASAYOSHI, additional, YOSHIDA, MOTOYUKI, additional, MORIOKA, CHIE, additional, FUJIMOTO, MASAO, additional, UEMURA, MASAHITO, additional, KAWARATANI, HIDETO, additional, TSUJIMOTO, TATSUHIRO, additional, and FUKUI, HIROSHI, additional

Published
2010
Full Text
View/download PDF

42. The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure

Author

Namisaki, Tadashi, primary, Yoshiji, Hitoshi, additional, Noguchi, Ryuichi, additional, Ikenaka, Yasuhide, additional, Kitade, Mitsuteru, additional, Kaji, Kosuke, additional, Aihara, Yosuke, additional, Yoshii, Junichi, additional, Yanase, Koji, additional, Tsujimoto, Tatsuhiro, additional, Kawaratani, Hideto, additional, Shirai, Yusaku, additional, Uemura, Masahito, additional, and Fukui, Hiroshi, additional

Published
2010
Full Text
View/download PDF

43. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma

Author

Yoshiji, Hitoshi, primary, Noguchi, Ryuichi, additional, Toyohara, Masahisa, additional, Ikenaka, Yasuhide, additional, Kitade, Mitsuteru, additional, Kaji, Kosuke, additional, Yamazaki, Masaharu, additional, Yamao, Junichi, additional, Mitoro, Akira, additional, Sawai, Masayoshi, additional, Yoshida, Motoyuki, additional, Fujimoto, Masao, additional, Tsujimoto, Tatsuhiro, additional, Kawaratani, Hideto, additional, Uemura, Masahito, additional, and Fukui, Hiroshi, additional

Published
2009
Full Text
View/download PDF

44. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report

Author

Mashitani, Tsuyoshi, primary, Yoshiji, Hitoshi, additional, Yamazaki, Masaharu, additional, Ikenaka, Yasuhide, additional, Noguchi, Ryuichi, additional, Ishikawa, Masatoshi, additional, Kawaratani, Hideto, additional, Matsuo, Norihide, additional, Uemura, Masahito, additional, Yamao, Junichi, additional, Fujimoto, Masao, additional, Mitoro, Akira, additional, Toyohara, Masahisa, additional, Yoshida, Motoyuki, additional, Sawai, Masayoshi, additional, Morioka, Chie, additional, Tsujimoto, Tatsuhiro, additional, Kitade, Mitsuteru, additional, Kaji, Kosuke, additional, Aihara, Yosuke, additional, and Fukui, Hiroshi, additional

Published
2009
Full Text
View/download PDF

46. Crosstalk between angiogenesis, cytokeratin-18, and insulinresistance in the progression of non-alcoholic steatohepatitis

Author

Kitade, Mitsuteru, primary, Yoshiji, Hitoshi, additional, Noguchi, Ryuichi, additional, Ikenaka, Yasuhide, additional, Kaji, Kosuke, additional, Shirai, Yusaku, additional, Yamazaki, Masaharu, additional, Uemura, Masahito, additional, Yamao, Junichi, additional, Fujimoto, Masao, additional, Mitoro, Akira, additional, Toyohara, Masahisa, additional, Sawai, Masayoshi, additional, Yoshida, Motoyuki, additional, Morioka, Chie, additional, Tsujimoto, Tatsuhiro, additional, Kawaratani, Hideto, additional, and Fukui, Hiroshi, additional

Published
2009
Full Text
View/download PDF

47. Potential Role of Enhanced Cytokinemia and Endotoxemia on the Decreased Activity of Plasma ADAMTS13 in Patients with Alcoholic Hepatitis.

Author

Ishikawa, Masatoshi, primary, Uemura, Masahito, primary, Matsuyama, Tomomi, primary, Matsumoto, Masanori, primary, Fujimoto, Masao, primary, Ishizashi, Hiromichi, primary, Kato, Seiji, primary, Morioka, Chie, primary, Tsujimoto, Tatsuhiro, primary, Kitazawa, Toshiyuki, primary, Kawaratani, Hidehito, primary, Fujimura, Yoshihiro, primary, and Fukui, Hiroshi, primary

Published
2008
Full Text
View/download PDF

48. Decreased Activity of Plasma ADAMTS13 Parallels Enhanced Endotoxemia in Patients with Severe Acute Pancreatitis: Relationship to Multiorgan Failure

Author

Morioka, Chie, primary, Uemura, Masahito, primary, Matsuyama, Tomomi, primary, Matsumoto, Masanori, primary, Fujimoto, Masao, primary, Kato, Seiji, primary, Ishikawa, Masatoshi, primary, Ishizashi, Hiromichi, primary, Tsujimoto, Tatsuhiro, primary, Kawaratani, Hideto, primary, Okuchi, Kazuo, primary, Nishio, Kenji, primary, Fujimura, Yoshihiro, primary, and Fukui, Hiroshi, primary

Published
2008
Full Text
View/download PDF

49. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis

Author

Matsumoto, Masanori, primary, Ishizashi, Hiromichi, primary, Kato, Seiji, primary, Matsuyama, Tomomi, primary, Isonishi, Ayami, primary, Ishikawa, Masatoshi, primary, Yagita, Masato, primary, Morioka, Chie, primary, Yoshiji, Hitoshi, primary, Tsujimoto, Tatsuhiro, primary, Kurumatani, Norio, primary, Fukui, Hiroshi, primary, Uemura, Masahito, additional, and Fujimura, Yoshihiro, additional

Published
2008
Full Text
View/download PDF

50. Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis

Author

Morioka, Chie, primary, Uemura, Masahito, additional, Matsuyama, Tomomi, additional, Matsumoto, Masanori, additional, Kato, Seiji, additional, Ishikawa, Masatoshi, additional, Ishizashi, Hiromichi, additional, Fujimoto, Masao, additional, Sawai, Masayoshi, additional, Yoshida, Motoyuki, additional, Mitoro, Akira, additional, Yamao, Junichi, additional, Tsujimoto, Tatsuhiro, additional, Yoshiji, Hitoshi, additional, Urizono, Yasuyuki, additional, Hata, Michiaki, additional, Nishino, Kenji, additional, Okuchi, Kazuo, additional, Fujimura, Yoshihiro, additional, and Fukui, Hiroshi, additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results